6/10/2008 | SS | Encysive Pharmaceuticals becomes wholly owned subsidiary of Pfizer
|
4/15/2008 | SS | Pfizer completes subsequent tender offer for Encysive shares; $195 million merger nears completion
|
4/8/2008 | SS | Pfizer extends subsequent offering period for Encysive
|
4/7/2008 | SS | Pfizer's subsequent offer for remaining Encysive shares ends Monday
|
4/1/2008 | SS | Pfizer subsidiary acquires 86.8% of Encysive's shares through tender offer, begins subsequent offer
|
3/4/2008 | SS | Pfizer begins tender offer for Encysive
|
2/20/2008 | CV | Market Commentary: Convertibles thinly traded amid weaker tone; Suntech, Level 3 lower; Encysive surges
|
2/20/2008 | SS | Pfizer expects to boost revenue from European market with $195 million acquisition of Encysive
|
2/20/2008 | SS | Market Commentary: Pfizer doubles Encysive share price; line is dead for 3Com; Microsoft hires proxy muscle
|
8/21/2007 | PP | Market Commentary: Beijing Med-Pharm announces $32.61 million sale; Qiao Xing Universal Telephone pockets $25 million
|
8/21/2007 | PP | New Issue: Encysive Pharmaceuticals plans $15 million stock placement
|
7/17/2007 | CV | Market Commentary: KKR credit concerns; Intel active again; Encysive looking up; investors on hold for earnings
|
7/17/2007 | SS | Encysive to consider alternatives
|
7/17/2007 | SS | Market Commentary: Lyondell deal pushes Nova; Pogo pops, Plains plunges; Encysive up; NovaStar falls
|
6/20/2007 | CV | Market Commentary: CVRD gains early; Encysive firmer; Panda delays deal; Stewart, Dollar Financial, NovaMed plan deals
|
6/18/2007 | CV | Market Commentary: Encysive up on hedge as FDA rejects drug; Cadence off as buyout falters; VeriFone, Panda quiet in gray
|
11/6/2006 | BT | Encysive launches Thelin in U.K.; remains hopeful U.S. launch will follow soon
|
11/2/2006 | BT | Encysive burns $25.5 million of cash reserve during Q3, looks to raise more
|
10/20/2006 | BT | Market Commentary: BioVex IPO pulled; Ariad dives; Encysive off; Vical spikes 10%; Amgen higher ahead of results
|
10/20/2006 | PP | Market Commentary: Lev stock climbs on $21 million stock offering; Encysive seals $75 million equity line
|
10/20/2006 | BTPP | New Issue: Encysive releases terms on $75 million equity line
|
10/19/2006 | BTPP | New Issue: Encysive Pharmaceuticals receives $75 million equity line
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/15/2006 | BT | Market Commentary: Vertex slips but deal a hit; Barrier, Auxilium rise on PIPEs deals; ImClone, Encysive, Arena higher
|
8/11/2006 | BT | Encysive to sell Thelin in Europe
|
8/11/2006 | BT | Market Commentary: Encysive spikes, slips to red; SkyePharma still looking for buyer; Pharmacyclics sinks
|
8/10/2006 | BT | Encysive gets European marketing approval for hypertension drug
|
8/8/2006 | BT | Market Commentary: Barrier loses 13%; Teva up more than 5%; Antigenics comes off highs; Amylin falls 7%
|
8/7/2006 | BT | Encysive says it will need to raise cash, reports $28.0 million second quarter net loss
|
8/7/2006 | BT | Market Commentary: Encysive sinks on dilution worries; Acorda higher; Genitope gains; Ariad off
|
7/25/2006 | BT | Market Commentary: Encysive plunges 40%; Momenta gains 38%; Nastech rises; Enzon up; Connetics firms
|
7/25/2006 | CV | Market Commentary: SanDisk jumps with strong earnings; Amylin in line after notes called; UAL prices $726 million deal
|
7/24/2006 | BT | Encysive receives new approvable letter for Thelin, one issue unresolved
|
7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
6/15/2006 | BT | Encysive's Thelin receives class 1 review from FDA
|
6/15/2006 | CV | Market Commentary: Omnicare, Encysive climb on positive regulatory news; SanDisk gains on upgrade; Synaptics up in line
|
6/2/2006 | BT | Encysive Pharmaceuticals' Thelin gets positive opinion from European authorities
|
6/2/2006 | BT | Market Commentary: Encysive stock skyrockets on nod from European agency; Alphatec stock slips on IPO
|
6/2/2006 | CV | Market Commentary: Trinity gains on debut; Novell improves further on volatility, takeover speculation; Encysive gains outright
|
5/26/2006 | BT | Market Commentary: Anadys spikes on thin volume; Cubist extends gain on Cubicin nod; Tanox, Momenta, Epix up
|
5/25/2006 | BT | Encysive submits complete response to FDA on New Drug Application for Thelin
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/25/2006 | CV | Market Commentary: Encysive gains outright on FDA submission; Omnicare, XM Satellite better on hedge amid stock declines
|
5/10/2006 | BT | Encysive reports first-quarter net loss increases to near $30 million, says Thelin remains priority this year
|
3/24/2006 | BT | Encysive receives approvable letter from FDA for Thelin
|
3/24/2006 | BT | Market Commentary: BioMarin shares, new bonds gain; Cephalon loses 13%; Idenix falls 28%; King slips; Encysive declines
|
3/23/2006 | BT | Encysive puts trials of TBC3711 on hold after "unusual finding"
|
3/6/2006 | BT | Encysive to start Thelin clinical trial in patients with diastolic heart failure
|
1/13/2006 | BT | Market Commentary: Nektar up over 10% on Pfizer's move; Encysive, Alexion up big; Biopure loses 4% after follow-on
|
1/11/2006 | CV | Market Commentary: Convertibles market remains mixed; Intel weaker; Connetics, Ford better
|
1/9/2006 | BT | Encysive announces start of enrollment for tests of hypertension drug TBC3711
|
12/13/2005 | BT | Encysive completes phase 3 trials for Thelin in pulmonary arterial hypertension; regulatory reviews pending
|
12/12/2005 | BT | Market Commentary: MedImmune up on flu drug data; Merck stock off on Vioxx mistrial; Encysive falls on Myogen's gain
|
11/29/2005 | BT | Encysive nearly doubles workforce preparing for launch of Thelin
|
11/29/2005 | BT | Market Commentary: InterMune, Valeant slip; Voyager IPO chatted up; Encysive higher; Dendreon, ViroPharma decline
|
9/27/2005 | BT | Market Commentary: Sunesis sinks after below-range IPO; Biogen, Elan bounce then retreat; Genentech sharply lower
|
6/21/2005 | BT | Market Commentary: Critical Therapeutics zooms after financing round; Mylan launches bank facility; Eyetech seen higher
|
3/16/2005 | CV | Encysive greenshoe exercised, raising convertibles to $130 million
|
3/11/2005 | CV | New Issue: Encysive sells upsized $115 million convertible at 2.5%, up 35%
|
3/11/2005 | CV | Market Commentary: JetBlue underwater; Encysive last seen at 101 bid; oilpatch issues in flux; Tech Data falls; Best Buy off
|
3/10/2005 | CV | Market Commentary: Delta weighs on airlines; JetBlue new issue quiet in gray; Playboy at 101; Encysive bid up
|
3/9/2005 | CV | Market Commentary: JetBlue, Encysive Pharma, Semco deals emerge; Playboy fetches an offer, bids faint; Nash Finch on tap
|
3/9/2005 | CV | Encysive Pharma $100 million convertible talked to yield 2.25%-2.75%, up 30%-35%
|